Want to see JP:4892 full AI Analyst Report?

Cyfuse Biomedical K.K. (4892) Price & Analysis

0 Followers

4892 Stock Chart & Stats

¥590.00

¥1.00(0.23%)

At close: Jan 08 4:00 PM EST

¥590.00

¥1.00(0.23%)

Day’s Range― - ―

52-Week Range¥509.00 - ¥764.00

Previous CloseN/A

Volume38.50K

Average Volume (3M)50.89K

Market Cap

¥5.28B

Enterprise Value¥2.22B

Total Cash (Recent Filing)¥3.53B

Total Debt (Recent Filing)¥1.24B

Price to Earnings (P/E)―

Beta0.57

Next Earnings

Aug 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-89.44

Shares Outstanding10,092,100

10 Day Avg. Volume43,580

30 Day Avg. Volume50,893

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)1.88

Price to Sales (P/S)22.48

P/FCF Ratio-8.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Revenue ReboundA large, sustained revenue rebound signals accelerating commercial adoption of core products and services. If sustained, higher top-line scale can support R&D investment, improve operating leverage potential, and reduce dependence on external funding over the medium term.

Differentiated Platform TechnologyA proprietary scaffold-free 3D cell assembly platform creates a durable competitive edge in regenerative medicine and research markets. Platform orientation supports product, service, and partnership revenue streams and raises switching costs for researchers and collaborators.

Manageable Leverage And Asset BaseA moderate debt-to-equity ratio and a sizable equity and asset base provide a cushion to absorb near-term losses and fund strategic initiatives. This balance-sheet scale supports continued R&D and commercialization efforts while the company works toward profitability.

Bears Say

Deep Persistent UnprofitabilityVery large operating and net losses indicate a cost structure that is not yet scalable relative to revenue. Persistent unprofitability erodes equity, increases dilution risk, and constrains the firm's ability to self-fund growth absent sustained margin improvement.

Negative Operating And Free Cash FlowConsistent negative operating and free cash flows mean the business relies on external financing to run operations. This undermines financial flexibility, raises execution risk for scaling commercial operations, and creates ongoing refinancing or dilution exposure.

Rising Debt Increases Financing RiskMaterial growth in debt while losses persist raises refinancing and interest-expense risk. Higher leverage reduces capital allocation flexibility, heightens sensitivity to funding markets, and can pressure liquidity if operational performance fails to improve.

4892 FAQ

What was Cyfuse Biomedical K.K.’s price range in the past 12 months?

Cyfuse Biomedical K.K. lowest stock price was ¥509.00 and its highest was ¥764.00 in the past 12 months.

What is Cyfuse Biomedical K.K.’s market cap?

Cyfuse Biomedical K.K.’s market cap is ¥5.28B.

When is Cyfuse Biomedical K.K.’s upcoming earnings report date?

Cyfuse Biomedical K.K.’s upcoming earnings report date is Aug 14, 2026 which is in 15 days.

How were Cyfuse Biomedical K.K.’s earnings last quarter?

Cyfuse Biomedical K.K. released its earnings results on May 15, 2026. The company reported -¥22.56 earnings per share for the quarter, missing the consensus estimate of N/A by -¥22.56.

Is Cyfuse Biomedical K.K. overvalued?

According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyfuse Biomedical K.K. pay dividends?

Cyfuse Biomedical K.K. does not currently pay dividends.

What is Cyfuse Biomedical K.K.’s EPS estimate?

Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyfuse Biomedical K.K. have?

Cyfuse Biomedical K.K. has 10,092,100 shares outstanding.

What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?

Cyfuse Biomedical K.K. reported an EPS of -¥22.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.622%.

Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?

Currently, no hedge funds are holding shares in JP:4892

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cyfuse Biomedical K.K.

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.